Higher ADK levels track stronger triciribine effects in leukemia cells, pointing to a potential biomarker
In a comprehensive study of acute lymphoblastic leukemia, researchers at Karolinska Institutet have shown that the enzyme ADK plays an important role in determining how leukemia cells respond to triciribine. Published in npj Precision Oncology, the study also provides new insights into how the compound works and identifies ADK as a potential biomarker for predicting its effects on leukemia cells.
A recent study by researchers at Karolinska Institutet has uncovered a potential biomarker for triciribine's effectiveness in treating acute lymphoblastic leukemia. The enzyme ADK plays a crucial role in determining how leukemia cells respond to triciribine treatment. The study, published in npj Precision Oncology, found that higher levels of ADK were associated with stronger triciribine effects in leukemia cells.
Triciribine works by activating ADK, which in turn disrupts key processes needed for leukemia cell growth and division, such as DNA and RNA precursor synthesis. While the study provides promising insights, it remains to be seen whether ADK can accurately predict treatment response in actual patients.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
